Previous 10 | Next 10 |
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference PR Newswire CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision...
2023-08-29 18:30:23 ET Summary Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves and ongoing trials support the development of it...
2023-08-11 16:23:04 ET More on Tyra Biosciences Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy Tyra Biosciences soars over 50% on public debut Precision oncolog...
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights PR Newswire -Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study o...
2023-08-01 10:23:02 ET Tyra Biosciences ( NASDAQ: TYRA ) said that the US Food and Drug Administration has granted orphan drug status to its lead drug candidate TYRA-300 in the treatment of achondroplasia, the most common form of dwarfism. The biotech company said it is prepar...
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia PR Newswire CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing...
2023-06-01 05:25:45 ET Summary TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not have clinical data yet. Tyra Biosciences ( TYRA ) develops precision medicines usin...
2023-05-04 18:14:03 ET Tyra Biosciences press release ( NASDAQ: TYRA ): Q1 GAAP EPS of -$0.28 beats by $0.09 . As of March 31, 2023, TYRA had cash and cash equivalents of $241.7 million that will support TYRA through important clinical and operational milestones over a...
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights PR Newswire -SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track ...
Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire CARLSBAD, Calif. , March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medic...
News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Inc. Company Name:
TYRA Stock Symbol:
OTCMKTS Market:
Tyra Biosciences Inc. Website:
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) PR Newswire - In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remain...
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...